A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma

Clinical and Translational Oncology

Volumn 17, Issue 9, 2015, Pages 743-750

  Sepulveda J M ^a   Belda Iniesta, C ^b   Gil Gil, M ^c   Perez Segura P ^d   Berrocal, A ^e   Reynes G ^f   Gallego, O ^g   Capellades, J ^h   Ordonez J M ⁱ   La Orden, B ⁱ   Balana C ^j  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b Hospital Madrid Norte Sanchinarro   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h HOSPITAL DEL MAR   (Spain)

ⁱ Roche Farma SA   (Spain)

^j HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

more..

Author keywords

Bevacizumab; Glioblastoma; Recurrent; Temozolomide

Indexed keywords

BEVACIZUMAB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE;

ADULT; AGED; ARTICLE; BLEEDING; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; HYPERTENSION; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TOXICITY TESTING; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; FEASIBILITY STUDY; FOLLOW UP; HEMATOLOGIC DISEASE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BRAIN NEOPLASMS; DACARBAZINE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84938980063     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-015-1304-0     Document Type: Article

References (25)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.
3. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004;10(6):1871–4.
4. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.
5. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17(8):2572–8.
6. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–40.
7. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740–5.
8. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy: temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–22.
9. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708.
10. Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE 2nd, Bailey L, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer. 2012;118(5):1302–12.
11. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722–9.
12. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007;25(22):3357–61.
13. Wick W, Steinbach JP, Küker WM, Dichgans J, Bamberg M, Weller M. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology. 2004;62(11):2113–5.
14. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59(4):793–7.
15. Herrmann BG, Frischauf AM. Isolation of genomic DNA. Methods Enzymol. 1987;152:180–3.
16. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277–80.
17. Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer. 2008;112(10):2267–73.
18. Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009;110(1):173–80.
19. Raizer JJ, Grimm S, Chamberlain MC, Nicholas MK, Chandler JP, Muro K, et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer. 2010;116(22):5297–305.
20. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253–9.
21. Jeremic B, Grujicic D, Antunovic V, Djuric L, Stojanovic M, Shibamoto Y. Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. J Neurooncol. 1994;21(2):177–85.
22. Nitta T, Sato K. Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer. 1995;75(11):2727–31.
23. Quigley MR, Flores N, Maroon JC, Sargent B, Lang S, Elrifai A. Value of surgical intervention in the treatment of glioma. Stereotact Funct Neurosurg. 1995;65(1–4):171–5.
24. Verhoeff JJ, Lavini C, van Linde ME, Stalpers LJ, Majoie CB, Reijneveld JC, et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol. 2010;21(8):1723–7.
25. Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, et al. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol. 2010;12(3):289–96.